Latest press releases Nov 14 2023 MoonLake Immunotherapeutics Reports Third Quarter 2023 Financial Results and Provides a Business Update Nov 05 2023 MoonLake Immunotherapeutics announces landmark Phase 2 results for Nanobody® sonelokimab in active psoriatic arthritis Oct 15 2023 MoonLake Immunotherapeutics announces the full dataset from its 24-week MIRA clinical trial, establishing the Nanobody® sonelokimab as a highly promising and differentiated therapeutic solution for Hidradenitis Suppurativa View All News View All Press Releases + Upcoming events Jan 8 - Jan 11 2024 JP Morgan 42nd Annual Healthcare Conference View All Events View All Events + Corporate presentations ARGO Week 12 Results MIRA Week 24 Results Corporate presentation - October 2023 v2 View All Presentations View All Presentations + IR contact details Dr. Atif Khan, Director of Strategic Planning and Projects e: ir@moonlaketx.com
Nov 14 2023 MoonLake Immunotherapeutics Reports Third Quarter 2023 Financial Results and Provides a Business Update
Nov 05 2023 MoonLake Immunotherapeutics announces landmark Phase 2 results for Nanobody® sonelokimab in active psoriatic arthritis
Oct 15 2023 MoonLake Immunotherapeutics announces the full dataset from its 24-week MIRA clinical trial, establishing the Nanobody® sonelokimab as a highly promising and differentiated therapeutic solution for Hidradenitis Suppurativa
MoonLake
MoonLake
